In summary, our data show that compared to no administration of G‐CSF, administration of G‐CSF significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT but was significantly associated with a higher risk of grades II–IV acute GVHD, irrespective of graft type. The gene discussed is CSF3; the disease is acute graft versus host disease.